Table 2:
Baseline characteristics—patients diagnosed with INS in adulthood.
| Characteristics | Overall (N = 374) | SSNS [n = 266 (71%)] | PSRNS [n = 36 (10%)] | SSRNS [n = 4 (1%)] | INS, steroids not tried [n = 60 (16%)] | INS, unknown response to steroids [n =8 (2%)] |
|---|---|---|---|---|---|---|
| Sex, n (%) | ||||||
| Male | 189 (51) | 131 (49) | 18 (50) | 2 (50) | 32 (53) | 6 (75) |
| Female | 185 (49) | 135 (51) | 18 (50) | 2 (50) | 28 (47) | 2 (25) |
| Ethnicity | ||||||
| White | 302 (81) | 215 (81) | 29 (81) | 3 (75) | 50 (83) | 5 (62) |
| Asian (Pakistani, Indian or Bangladeshi background) | 39 (10) | 28 (11) | 4 (11) | 1 (25) | 4 (7 | 2 (25) |
| Black African, Black Caribbean or other Black background | 20 (5) | 11 (4) | 3 (8) | 0 | 5 (8) | 1 (12) |
| Mixed ethnicity | 2 (<1) | 2 (<1) | 0 | 0 | 1 (1.7) | 0 |
| Other ethnicity | 5 (1) | 4 (2) | 0 | 0 | 0 | 0 |
| Asian (Chinese or other Asian background) | 5 (1) | 5 (2) | 0 | 0 | 0 | 0 |
| Patient declined to answer | 1 (<1) | 1 (<1) | 0 | 0 | 0 | 0 |
| IMDQ (England),, n (%) | ||||||
| 1 | 60 (20) | 43 (19) | 11 (33) | 0 | 5 (12) | 1 (17) |
| 2 | 54 (18) | 37 (17) | 6 (18) | 1 (25) | 8 (20) | 2 (33) |
| 3 | 68 (22) | 51 (23) | 6 (18) | 1 (25) | 10 (24) | 0 |
| 4 | 62 (20) | 43 (19) | 5 (15) | 1 (25) | 11 (27) | 2 (33) |
| 5 | 62 (20) | 48 (22) | 5 (15) | 1 (25) | 7 (17) | 1 (17) |
| Age at diagnosis (years), median (IQR) | 42 (30–58) | 46 (31–60) | 38 (28–45) | 38 (34–44) | 37 (26–51) | 32 (29–40) |
| Age at recruitment (years), median (IQR) | 52 (39–65) | 54 (40–66) | 45 (35–54) | 53 (42–63) | 52 (39–62) | 49 (37–60) |
| Dialysis at recruitment, n (%) | 11 (3) | 5 (2) | 1 (3) | 0 | 5 (8) | 0 |
| Kidney transplant at recruitment, n (%) | 28 (8) | 8 (3) | 5 (14) | 0 | 11 (18) | 4 (50) |
| Transplant recurrence prior to recruitment, n (%) | 1 (<1) | 1 (<1) | 0 | 0 | 0 | 0 |
| Renal biopsy performed, n (%) | 352 (94) | 255 (96) | 33 (92) | 4 (100) | 52 (87) | 8 (100) |
| Histological diagnosis, n (%) | ||||||
| MCD | 187 (53) | 168 (66) | 11 (33) | 2 (50) | 5 (10) | 1 (12) |
| FSGS | 162 (46) | 84 (33) | 22 (67) | 2 (50) | 47 (90) | 7 (88) |
| Other | 3 (<1) | 3 (1) | 0 | 0 | 0 | 0 |
| Medications at recruitment, n (%) | ||||||
| Corticosteroids | 126 (34) | 108 (41) | 13 (36) | 0 | 2 (3) | 3 (38) |
| Calcineurin inhibitors | 103 (28) | 72 (27) | 13 (22) | 13 (36) | 2 (50) | 3 (38) |
| Mycophenolate mofetil | 25 (7) | 12 (5) | 4 (11) | 1 (25) | 6 (10) | 2 (25) |
| Cyclophosphamide | 2 (<1) | 1 (<1) | 1 (3) | 0 | 0 | 0 |
| Golimumab or adalimumab | 1 (<1) | 1 (<1) | 0 | 0 | 0 | 0 |
| Rituximab | 1 (<1) | 1 (<1) | 0 | 0 | 0 | 0 |
| Pazopanib | 1 (<1) | 0 | 1 (3) | 0 | 0 | 0 |
| Warfarin, direct oral anticoagulant or heparin | 33 (9) | 23 (9) | 5 (14) | 0 | 2 (3) | 2 (25) |
| Antiplatelet | 49 (13) | 34 (13) | 6 (17) | 0 | 7 (12) | 2 (25) |
| Statin | 133 (36) | 91 (34) | 17 (47) | 1 (25) | 22 (37) | 2 (25) |
| Renin–angiotensin system inhibitor | 195 (52) | 133 (50) | 22 (61) | 2 (50) | 34 (57) | 4 (50) |